Page 103 - Read Online

Page 14 of 17 Rastogi. Hepatoma Res 2020;6:47 I http://dx.doi.org/10.20517/2394-5079.2020.35

2019;11:1-18.
12. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of
804 North American patients. Am J Clin Pathol 1996;105:65-75.
13. Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, et al: Repeat hepatectomy for colorectal liver metastases. Ann Surg
1997;225:51-60; discussion 60-2.
14. Hadjittofi C, Athanasopoulos PG, Koti RS, Konstantinidou SK, Davidson BR. Long-term survival with repeated resections of recurrent
hepatocellular carcinoma in a non-cirrhotic liver: case report and brief review of the literature. Ann Transl Med 2016;4:112.
15. el-Refaie A, Savage K, Bhattacharya S, Khakoo S, Harrisson TJ, et al. HCV-associated hepatocellular carcinoma without cirrhosis. J
Hepatol 1996;24:277-85.
16. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology
2000;271:197-204.
17. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87.
18. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-54.
19. Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir
treatment. Gastroenterology 2013;144:933-44.
20. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
21. Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update.
Hepatology 2011;53:1020-2.
22. Park JS, Yang JM, Min MK. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras
oncogene. Biochem Biophys Res Commun 2000;267:581-7.
23. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995;69:3893-6.
24. Lee DH, Lee JM. Primary malignant tumours in the non-cirrhotic liver. Eur J Radiol 2017;95:349-61.
25. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol
2012;56:1384-91.
26. Thompson SM, Garg I, Ehman EC, Sheedy SP, Bookwalter CA, et al. Non-alcoholic fatty liver disease-associated hepatocellular
carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. Br J Radiol 2018;91:20180345.
27. Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, et al. Non-alcoholic fatty liver disease progressesto hepatocellular carcinoma in the
absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
28. Adami HO, Hsing AW, Mclaughlin JK, Trichopoulos D, Hacker D, et al. Alcoholism and liver cirrhosis in the etiology of primary liver
cancer. Int J Cancer 1992;51:898-902.
29. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni Jr JF, editors. Cancer epidemiology and prevention. New York:
Oxford University Press; 1996. pp. 772-93.
30. Burra P, Zanetto A, Germani G. Liver transplantation for alcoholic liver disease and hepatocellular carcinoma. Cancers (Basel)
2018;10:46.
31. Jiang HY, Chen J, Xia CC, Cao LK, Duan T, et al. Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World
J Gastroenterol 2018;24:2348-62.
32. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, et al. From cirrhosis to hepatocellular carcinoma: new molecular insights on
inflammation and cellular senescence. Liver Cancer 2013;2:367-83.
33. Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, et al. Analysis of notch and TGF-β signaling expression in different
stages of disease progression during hepatitis B virus infection. Clin Transl Gastroenterol 2012;3:e23.
34. Turlin B, Juguet F, Moirand R, Le Quilleuc D, Loréal O, et al. Increased liver iron stores in patients with hepatocellular carcinoma
developed on a noncirrhotic liver. Hepatology 1995;22:446-50.
35. Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Canc 2017; 48:238-40.
36. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on
noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006;194:594-9.
37. Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380:1450-62.
38. Zheng C, Zeng H, Lin H, Wang J, Feng X, et al. Serum microcystin levels positively linked with risk of hepatocellular carcinoma: a case-
control study in southwest China. Hepatology 2017;66:1519-28.
39. Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma?
Clinicopathologic analysis. Mod Pathol 2014;27:420-32.
40. Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, et al. Androgen-induced hepatoma. Lancet 1975;22:430-2.
41. Trevisani F, D’Intino PE, Caraceni P, Pizzo M, Stefanini GF, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma.
Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995;75:2220-32.
42. Lee Y, Park H, Lee H, Cho JY, Yoon YS, et al. The clinicopathological and prognostic significance of the gross classification of
hepatocellular carcinoma. J Pathol Transl Med 2018;52:85-92.
43. Kojiro M. Pathology of hepatocellular carcinoma. Hoboken:Wiley; 2009. pp. 1-184.
44. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with
distinctive clinico-pathologic features. Cancer 1980;46:372-9.
45. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic